Reuters logo
BRIEF-Argenx says FDA grants orphan drug designation for ARGX-113
September 25, 2017 / 10:49 AM / 2 months ago

BRIEF-Argenx says FDA grants orphan drug designation for ARGX-113

Sept 25 (Reuters) - Argenx NV

* Argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below